Research lines

• Dual pathways to insulin replacement: artificial pancreas and beta cell biology

  Directed by Rosa Gasa

  We combine clinically used artificial‑pancreas technologies with basic research aimed at understanding how beta-cell mass is regulated and how substitute insulin-producing cells can be generated. This dual program advances current diabetes management through automated insulin delivery while developing foundational biological knowledge needed to create future cell‑replacement therapies capable of restoring endogenous insulin production.

• Metabolic diseases, organ damage, and cardiovascular risk

  Directed by Josep Vidal 

  We combine clinical and laboratory research to understand how diabetes, dyslipidemia, and obesity lead to organ damage, with a special but not exclusive focus on cardiovascular disease.  We study how and by what mechanisms different therapeutic strategies can minimize such damage. With a better understanding of the pathophysiology of metabolic diseases-associated organ damage, we aim at improving and personalizing therapies for people living with these diseases.